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Abstract The objective of this work was to combine the
advantages of the dried blood spot (DBS) sampling process
with the highly sensitive and selective negative-ion chemical
ionization tandem mass spectrometry (NICI-MS-MS) to
analyze for recent antidepressants including fluoxetine, nor-
fluoxetine, reboxetine, and paroxetine from micro whole
blood samples (i.e., 10 μL). Before analysis, DBS samples
were punched out, and antidepressants were simultaneously
extracted and derivatized in a single step by use of
pentafluoropropionic acid anhydride and 0.02% triethylamine
in butyl chloride for 30 min at 60 °C under ultrasonication.
Derivatives were then separated on a gas chromatograph
coupled with a triple-quadrupole mass spectrometer operating
in negative selected reaction monitoring mode for a total run
time of 5min. To establish the validity of themethod, trueness,
precision, and selectivity were determined on the basis of the
guidelines of the “Société Française des Sciences et des
Techniques Pharmaceutiques” (SFSTP). The assay was found
to be linear in the concentration ranges 1 to 500 ng mL−1 for
fluoxetine and norfluoxetine and 20 to 500 ng mL−1 for
reboxetine and paroxetine. Despite the small sampling
volume, the limit of detection was estimated at 20 pg mL−1
for all the analytes. The stability of DBS was also evaluated
at −20 °C, 4 °C, 25 °C, and 40 °C for up to 30 days.
Furthermore, the method was successfully applied to a
pharmacokinetic investigation performed on a healthy vol-
unteer after oral administration of a single 40-mg dose of
fluoxetine. Thus, this validated DBS method combines an
extractive—derivative single step with a fast and sensitive
GC-NICI-MS-MS technique. Using microliter blood samples,
this procedure offers a patient-friendly tool in many biomed-
ical fields such as checking treatment adherence, therapeutic
drug monitoring, toxicological analyses, or pharmacokinetic
studies.
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Introduction
Until 1980, the first line of depression treatment was tricyclic
antidepressants and monoamine oxidase inhibitors. Their
pharmacological action was attributed to increasing the
synaptic concentration of the noradrenergic and serotonergic
neurotransmitters. However, these compounds present many
side effects due to binding to multiple receptors, cardio-
toxicity and diverse drug-drug interactions that may lead to
severe intoxication [1, 2].
In 1980, an important new class of antidepressants was
introduced, the selective serotonin reuptake inhibitors
(SSRIs), including fluoxetine and paroxetine. This class
has become a mainstay of antidepressant treatment due to
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its better safety and tolerability [1]. More recently, newer
antidepressants have been developed, including noradrenergic
reuptake inhibitors (NaRIs) such as reboxetine.
However, even if these new compounds have fewer
undesirable effects, they are frequently used in deliberate
self-poisoning and can lead to major intoxication [3–5].
Furthermore, some depressed patients do not respond to
their treatment, because of non-compliance or co-medication
with inducers of their enzymes [6, 7]. Thus, analysis of
antidepressants is required in many fields such as therapeutic
drug monitoring or forensic toxicology.
Traditionally, clinical and/or toxicological analyses are
performed using plasma obtained by venipuncture [8, 9];
however, this sampling form requires a hospital infrastruc-
ture and can be hazardous for the patient population where
venous collection is problematic [10]. Among alternative
sampling procedures, use of filter paper as a support for
blood collection seems to be a powerful and patient-friendly
tool.
Referred to as dried blood spot (DBS), this alternative
procedure was successfully introduced by Guthrie et al. in
1963 for collecting newborns’ capillary blood for the
neonatal screening of phenylketonurea. Since then, the
filter paper 903S&S produced by Whatman has been
introduced for multiple neonatal metabolic disorder screening
programs worldwide [11].
The DBS procedure offers the advantages, compared
with venipuncture, of being less invasive and more cost-
effective in terms of sample collection, shipment, and
storage [12, 13]. Indeed, blood samples are collected from a
small finger prick with an automatic lancet, enabling non-
hospital based sampling, so that patients can even perform
the sampling themselves at home [14, 15]. Furthermore, the
DBS sampling process does not require the use of
anticoagulant or plasma separation and ensures better
stability of the compounds during shipment and storage
without using a refrigeration device [16–18]. Security is
also improved by the deactivation of potential pathogens,
for example HIV virus, on the filter paper [15, 19, 20].
Because of these advantages, DBS was recently applied to
the monitoring of therapeutic agents including antimalarials,
antiepileptics, antiretrovirals, antidiabetics, and antibiotics
[8, 21–27].
An important analytical aspect to take in consideration
with the DBS procedure is the limited sample volume,
which may be problematic in terms of sensitivity, especially
at lower therapeutic concentration levels. This lack has to
be compensated by the use of highly sensitive detectors
such as triple-stage mass spectrometers operating in the
selected reaction monitoring (SRM) mode [28]. Although
the use of tandem mass spectrometry (MS-MS) with
atmospheric-pressure ionization (API) coupled to liquid
chromatography is known to be the gold standard for
quantification of pharmaceutical compounds [29, 30],
negative-ion chemical ionisation (NICI) combined with
gas chromatography (GC) is an interesting alternative.
Indeed, NICI has been demonstrated to be a very highly
sensitive and selective ionization mode [31–33], and has been
successfully applied to different classes of pharmaceutical
compounds, for example antidepressants, benzodiazepines,
opioids, and cannabinoids [34–39].
Nevertheless, NICI generally requires a derivatization
step to improve the electro-affinity of the analytes. This
step is often tedious and time-consuming. An important
part of this work was focused on optimization of the
derivatization step to decrease the sample preparation time.
Thus, derivatization of the antidepressants was combined in
a single step with extraction of the DBS.
This article describes a new efficient method for
quantitative monitoring of three antidepressants and one
phase I metabolite in whole blood by combining the DBS
sampling procedure with accelerated GC separation coupled
to NICI-MS-MS detection. Because of its high sensitivity and
selectivity, this approach is particularly interesting for clinical
and toxicological analyses because only 10 μL blood is
required.
Experimental
Chemicals and reagents
Fluoxetine, fluoxetine d6, norfluoxetine, and norfluoxetine
d6 at 1000 μg mL
−1 or 100 μg mL−1 in methanol were
purchased from Cambridge Isotope Laboratory (Andover,
USA). Reboxetine, paroxetine, and paroxetine d6 were
purchased from Sigma-Aldrich (Steinheim, Germany).
Reboxetine d5 was obtained from Toronto Research
Chemicals (North York, Canada).
Working standard solutions were prepared by dilution of
stock solutions with methanol to reach concentrations of
interest ranging from 1 to 10 μg mL−1, except for
deuterated compounds, used as internal standards (IS),
which were prepared in a vial by dilution with methanol to
reach concentrations of 250 ng mL−1 for fluoxetine d6 and
norfluoxetine d6 and 500 ng mL
−1 for both reboxetine d5
and paroxetine d6. After use, stock and working solutions
were stored at −20 °C.
Pentafluoropropionic anhydride (PFPA) 99% and trie-
thylamine 99%were obtained from Sigma-Aldrich (Bellefonte,
USA). All solvents used, for example hexane, methanol,
and butyl chloride, were of high-performance chromato-
graphic grade from Merck (Darmstadt, Germany) and
Romil (Obergoesgen, Switzerland). Human blood was
supplied by the Geneva University Hospitals (Geneva,
Switzerland); EDTA was used as anti-coagulant.
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DBS sample processing
Preparation of calibration standards and quality
control samples
Calibration standards (Cal) were prepared one day before
analysis. After evaporation of appropriate working standard
solutions previously added to Eppendorf tubes, antidepressant-
free EDTA—whole blood was added to reach a calibration
range of 1 to 500 ng mL−1 for both fluoxetine and
norfluoxetine and 20 to 500 ng mL−1 for both paroxetine and
reboxetine.
Quality controls (QC) were simultaneously and indepen-
dently prepared in the same way in our laboratory. Four QC
samples at concentrations of 1, 20, 250, and 500 ng mL−1
for both fluoxetine and norfluoxetine and 20, 40, 250, and
500 ng mL−1 for both paroxetine and reboxetine were
prepared one day before analysis, similarly to the calibration
standards.
Blood spotting
Real or spiked whole blood (10 μL) was spotted on a filter
paper card, item no. 105355097 from Whatman, Schleicher
and Schuell (Dassel, Germany), using a volumetric micro-
pipette (Eppendorf, Hamburg, Germany). The blood spots
were allowed to dry at room temperature for 2 h and then
packed in a sealable plastic bag containing a desiccant pad
until analysis. They were stored in the dark at ambient
temperature except for short-term stability experiments, in
which different temperatures were tested.
DBS sample preparation
Before analysis, DBS were punched out, and 5 μL IS was
added directly on to the disc. Extraction and derivatization
were performed simultaneously in a single step by adding
500 μL 0.02% triethylamine in butyl chloride and 100 μL
PFPA, followed by ultrasonication for 30 min at 60 °C.
The organic phase was then transferred into a conical vial
and evaporated to dryness under a stream of nitrogen.
Finally, the fluorinated derivatives were reconstituted with
50 μL hexane, and 2 μL was injected into the GC-MS
system.
GC-NICI-MS-MS analysis
Analyses were performed on a Varian (Walnut Creek, CA,
USA) CP 3800 gas chromatograph in combination with a
CTC Combi-PAL autosampler (Zwingen, Switzerland) and a
Varian 1200 L MS-MS triple-quadrupole mass spectrometer.
Data acquisition and analysis were performed using Varian
MS Workstation software (6.8).
Chromatographic conditions
Substances were separated using a fused-silica capillary
column (DB-5MS, 15 m×0.25 mm i.d., film thickness
0.25 μm), and high-purity helium (99.999%) was used as
the carrier gas with a constant flow of 1 mL min−1. For all
of the analyses, the injector temperature was set at 300 °C,
and splitless injection was used, with the injection purge
valve remaining closed for 1 min.
Under fast GC-MS-MS conditions, the initial column
temperature was set at 105 °C for 1 min, increased to 300 °C at
70° min−1, and held for 1.22 min for a total analysis time of
5 min.
Mass spectrometric detection
Methane (purity of 99.9995 %) was used as reagent gas for
NICI analyses at a pressure between 8 and 8.5 Torr.
Transfer line, manifold, and ion source were operated at
275, 40, and 150 °C, respectively. The mass spectrometer
was operated in the negative SRM mode with MS-MS
experiments based on collisionally induced dissociation
(CID) occurring in the collision cell (quadrupole 2), with an
argon collision gas pressure of 1.3 mTorr.
All MS-MS conditions are shown in Table 1. The
transitions chosen for each compound were based on
criteria of abundance and selectivity. The different NICI-
MS-MS conditions (reagent gas pressure, CID pressure,
collisional energy) were optimized with the use of
antidepressant standard solutions (data not presented here).
In fast GC mode, the duty cycle was set at 0.15 s to obtain a
sufficient number of work points to meet quantitative needs
(between 9 and 12 points).
Validation procedure
A full validation procedure for human dried blood spots
was conducted according to the guidelines of the “Société
Française des Sciences et des Techniques Pharmaceutiques”
(SFSTP) [40].
On each of three non-consecutive days, DBS Cal were
prepared in duplicate (n=2) at five concentration levels
(k=5; Cal=1, 20, 50, 150, and 500 ng mL−1 for both
fluoxetine and norfluoxetine, and Cal=20, 50, 150, 300,
and 500 ng mL−1 for reboxetine and paroxetine) for
determining the response function. Furthermore, DBS QC
were prepared independently in the same way in quadruplicate
(n=4) at four concentration levels (k=4; QC=1, 20, 250, and
500 ng mL−1 for both fluoxetine and norfluoxetine, and QC=
20, 40, 250, and 500 ng mL−1 for reboxetine and paroxetine),
representing the entire range of concentrations.
Validation enabled determination of specific criteria such
as trueness, precision, linearity, limit of quantification
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(LOQ), and limit of detection (LOD), which will be
discussed later.
Recovery and matrix effects
The efficiency of the procedure was evaluated by comparing
the absolute analyte peak area from DBS spiked with all
antidepressants at the concentration of 250 ng mL−1 1, with
the corresponding methanolic solutions spiked directly into
the extraction tube containing 2, or not 3, antidepressant-free
DBS specimen. Recovery and matrix effects were obtained
by using the 1/3 and the 2/3 ratios respectively [41]. For each
experiment, analyses were performed in triplicate.
Stability of DBS
To test the short-term stability of the antidepressants on
filter paper, three batches of antidepressant-free whole
blood were spiked with all the analytes at 250 ng mL−1.
DBS samples were prepared using the same procedure
described in the section “Blood spotting” and subsequently
stored at different temperatures (−20 °C, 4 °C, 21 °C, and
40 °C). Stability study was carried out over one month with
time points of 1, 3, 5, 15, and 30 days. For each time point,
DBS samples were analyzed in triplicate with a waiting
period of 12 h at ambient temperature before the analysis.
Pharmacokinetic investigation
The described procedure was applied to the monitoring of
fluoxetine and its main phase I metabolite norfluoxetine after
oral administration of a single 40-mg dose of fluoxetine (two
capsules of 20 mg Fluctine, Eli Lilly, Geneva, Switzerland) to
a healthy male volunteer (68 kg, 180 cm).
Capillary whole blood was collected at different time
points over one month using the DBS sampling process.
Except for the first day, all DBS samples were performed at
home by the volunteer himself after a finger prick made on
the top of the finger with a disposable lancet. At each time
point, five spots of 10 μL of capillary blood were collected
and stored on filter paper card using the procedure
described in the section “Blood spotting”. Last, filter paper
cards were sent to our laboratory by mail in a sealable
plastic bag containing a desiccant pad.
Because norfluoxetine is known to contribute to the
overall therapeutic and/or toxic effect [7, 31, 42, 43], both
the parent drug and the active metabolite were quantified
from DBS in duplicate for each time point. In addition,
pharmacokinetic parameters were estimated for these
analytes by a non-compartmental method using WinNonlin
version 4.1 (Pharsight, Mountainview, California, USA).
Pharmacokinetic parameters such as Cmax, Tmax, and t1/2
were calculated from standard equations using WinNonlin,
and AUC0-∞ was calculated using the trapezoidal rule.
Results and discussion
DBS sample preparation
Use of the DBS sampling process requires an extractive
step before analysis. The challenge is to remove the
compounds of interest from the filter paper and to retain
blood components. Generally, a mixture of water and
organic solvents, for example acetonitrile or methanol, is
employed [8, 15, 44, 45]. However, protic solvents are
unsuitable with the simultaneous use of acylation agents
such as fluorinated agents. Therefore, a large part of the
method development was focusing on the combination of
extraction solvent with fluorinated agent (i.e., PFPA) to
ensure an efficient and simple preparation step. In this way,
different aprotic solvents including butyl chloride, ethyl
Table 1 MS-MS conditions for antidepressants
Antidepressant Molecular mass compound/derivative (gmol−1) Q1 → Q3 (m/z) Collision energy (eV) Retention time (min)
Norfluoxetine d6 301/447 472 → 265 5 3.4
Norfluoxetine 295/441 421 → 161 15 3.4
421 → 259 10
Fluoxetine d6 315/461 441 → 161 5 3.5
Fluoxetine 309/455 435 → 161 5 3.5
435 → 306 15
Reboxetine d5 318/464 424 → 404 5 4.1
Reboxetine 313/459 419 → 109 10 4.1
419 → 137 15
Paroxetine d6 335/481 441 → 109 15 4.7
Paroxetine 329/475 435 → 109 15 4.7
435 → 137 15
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acetate, and hexane were tested for their extraction
capabilities. Under our selected conditions, butyl chloride
showed better results in terms of sensitivity (highest signal-
to-noise ratios) and selectivity. Additionally, the sonication
time and the temperature applied during the extraction-
derivatization single step were optimized. Thus, thirty
minutes of sonication at 60 °C represents the best
compromise in our case. Although the use of butyl chloride
resulted in poorer extraction recovery compared with water
or methanol for DBS application (data not shown), this aprotic
organic solvent enabled the simultaneous use of PFPA, thus
combining derivatization and extraction in a single step.
Fast GC-NICI-MS-MS
In the past several years, the development of a high-throughput
analytical method has become a laboratory standard. Numerous
studies have been published regarding theoretical approaches
to optimization of GC speed [46]. Depending on the resolution
required, it is possible to trade resolution for time [47]. In this
way, an attractive approach is to use a faster programming
temperature, which enables use of a narrow-bore column (i.e.,
0.25 mm), offering better robustness compared to a microbore
column when repeated injections of biological matrices are
carried out [32]. In our study, application of a 70° min−1
gradient enabled rapid and good separation, because the total
analysis time was 5 min, and the full widths at half-maximum
(FWHM) were about 0.6 s for each compound, which is in
agreement with fast GC requirements [47].
NICI is a highly selective and sensitive ionization mode
for compounds with a high electron affinity [32, 48].
Although any molecule is able to capture an electron, only
those with a positive electro-affinity will be stable enough
to be detected. Thus, the derivatization is an important step
in increasing the electro-affinity of the molecule and
improving sensitivity and selectivity. Moreover, the high
pressure of NICI contributes to thermalize the formed ion
owing to the multiple low-energy collisions. This aspect is
interesting when tandem mass spectrometry is used,
because precursor ions will have a lower internal energy
compared with other ionization modes such as electronic
impact. Figure 1 shows the product ion spectra obtained for
the antidepressants, which present few fragment ions and
consequently better sensitivity. This weak fragmentation is
interesting for these compounds, which have a low molecular
mass, although it provides at least two transitions required for
toxicological analysis (i.e., quantitation and identification).
In this work, the use of PFPA as fluorinated agents with
the NICI-MS-MS enables observation of a very intense
signal for our compounds of interest, although only 10 μL
of blood was used without any preconcentration step, in
contrast with the conventional procedure (see Fig. 2 and the
section “Selectivity, LOQ, and LOD”).
Validation
Response function
Response functions were determined by use of several
regression models [49, 50]. The best results were obtained
for weighted linear regression with a weight factor of 1/x2
for each compound.
Trueness and precision
The trueness and the precision of the method were
determined with independent QC DBS samples at each
concentration level. Hence, the trueness was determined by
calculating the percentage difference between experimental
and theoretical concentration values, indicating systematic
error. Precision which indicates random errors, was
assessed by computing the relative standard deviation for
the repeatability (RR.S.D.) and the between day variability,
expressed as the intermediate precision (IPR.S.D.) [49–51].
Repeatability represents the given precision under conditions
of repeatability (the same operator, the same samples, the
same reagents, etc.). The intermediate precision represents the
precision resulting from repetitions performed in a laboratory
on the same sample but under different conditions (here,
different days and reagents). As presented in Table 2, relative
bias, RR.S.D. and IPR.S.D. values were below 12% in
agreement with the SFSTP validation criteria.
Linearity and accuracy profiles
The linearity of an analytical method is its capacity to provide
results directly proportional to the concentration of the sample
within a certain concentration range [51]. Linearity was
calculated by fitting the back-calculated concentrations of the
QCs as a function of the introduced concentrations and by
applying the linear regression model based on the least-
squares method [50]. With coefficients of determination (r2)
above 0.9986 and slope values between 0.998 and 1.114, the
method was linear for the four antidepressants.
Figure 3 illustrates the relative accuracy profiles of the
four antidepressants. These profiles, built using total error
(bias and precision), provide an estimation of the uncer-
tainty measurement of the entire linearity range. A relative
error of 30% was selected as the acceptance threshold where
the expected proportion of measures (95%) was within the
acceptance limits. As depicted, all of the accuracy profiles are
between ±30%, demonstrating that the method is suitable for
performing clinical and toxicological analyses. For this
purpose, other antidepressants such as fluvoxamine, maproti-
line, and sertraline were tested with the described procedure
and preliminary results were satisfactory in terms of sensitiv-
ity and selectivity (data not shown). However, the lack of
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corresponding internal standard did not permit the inclusion of
these compounds in this study.
Selectivity, LOD, and LOQ
In order to test the selectivity of the method, six different
human blank DBSs were checked for interferences.
Figure 2B shows a typical total ion current chromatogram
of one blank DBS, demonstrating that no interfering peaks
were present at the retention times of the compounds of
interest. Carry-over was also investigated by injecting a
blank solution (hexane) after injection of twice the highest
calibration point. The results showed that no carry-over was
observed with our procedure (lower than 0.01%).
The sensitivity encountered was largely better than
therapeutic requirements, which enabled safe quantification
of the compounds with LOQ of 1 ng mL−1 for fluoxetine
and norfluoxetine and 20 ng mL−1 for reboxetine and
paroxetine (Figs. 2C–F), whereas the LODswere 20 pgmL−1
for each compound. LOQ was determined as the lowest QC
with trueness and precision under 15%, whereas LOD was
estimated as three times the signal-to-noise ratio (S/N).
Recovery and matrix effects
The results of the recovery and matrix effects investigations
are summarized in Table 3. As depicted, recoveries
obtained were acceptable for all compounds, even if
extraction and derivatization were combined into a single
step. Furthermore, no matrix effect was observed, which is
in agreement with the use of NICI [34].
Stability of DBS
Numerous methods have shown that DBS offered high
stability properties for many classes of compounds [15]. To
Fig. 1 Product-ion spectra of derivatives of the antidepressants after NICI ionization of: fluoxetine at a collision energy of 5 eV (a), norfluoxetine
at 15 eV (b), reboxetine at 10 eV (c), and paroxetine at 15 eV (d). Fragmentation pathways are proposed for each compound
Fig. 2 Total ion current
chromatograms of a blank
filter paper (a) and human
whole blood DBS (b), and
selected reaction monitoring
chromatograms of DBS
containing norfluoxetine at
1 ng mL−1 (c), fluoxetine at
1 ng mL−1 (d), reboxetine
at 20 ng mL−1 (e), and
paroxetine at 20 ng mL−1 (f)
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Table 2 Validation data
Antidepressant Nominal conc. (ng mL−1) Found conc. (ng mL−1) Relative bias (%) Repeatability
(RSD, %)
Intermediate precision
(RSD, %)
Norfluoxetine 1 0.99 −1.1 6.0 6.0
20 21.3 6.5 4.6 4.6
250 264 5.8 6.2 9.1
500 497 −0.6 9.7 11.9
Fluoxetine 1 0.99 −1.3 5.5 8.2
20 19.9 −0.5 8.5 8.5
250 272 8.7 6.2 6.2
500 550 10.1 2.5 7.6
Reboxetine 20 21.6 7.7 7.6 10.1
40 43.6 9.1 5.1 8.3
250 258 3.1 8.3 8.3
500 552 10.3 6.7 8.4
Paroxetine 20 21.4 7.0 6.5 9.8
40 38.5 −3.8 5.8 5.8
250 261 4.4 4.8 6.4
500 556 11.2 5.1 7.4
Fig. 3 Relative accuracy profiles of fluoxetine (a), norfluoxetine (b),
reboxetine (c), and paroxetine (d) with 1/x2 weight factor. The
continuous line represents the trueness, the dashed lines are the upper
and lower accuracy limits in relative values, and the dotted lines are
the upper and lower 30% tolerance limits
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the best of our knowledge, antidepressant stability has
never been investigated on filter paper.
Figure 4 shows good stability of fluoxetine, norfluoxetine,
reboxetine, and paroxetine in dried blood spots over 30 days,
as all tested DBS showed concentrations were between 85 and
115% of the initial concentration. Interestingly, no significant
difference was observed between the four investigated
temperatures, confirming that DBS can be stored at ambient
temperature for a relatively long time period. With these
Table 3 Recovery and matrix effects for the four antidepressants at
250 ng mL−1 (n=3)
Antidepressant Matrix effect (%) Recovery/RSD (%)
Norfluoxetine +1.7 81.6/3.8
Fluoxetine +4.1 73.2/3.0
Reboxetine −1.5 60.8/3.2
Paroxetine −3.0 89.6/2.2
Fig. 4 Stability of fluoxetine (a), norfluoxetine (b), reboxetine (c), and paroxetine (d) spiked at 250 ng mL−1 in DBS stored at −20 °C (crosses),
4 °C (squares), 20 °C (triangles), and 40 °C (circles)
Fig. 5 Concentration vs. time
profiles for fluoxetine
(triangles) and norfluoxetine
(squares) detected in DBS
samples collected from a
volunteer after oral
administration of a single 40-mg
dose of fluoxetine
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considerations, the DBS sampling process provides a powerful
tool in terms of storage and shipment of antidepressants
because sampling can be performed in a non-hospital based
environment, where refrigeration is problematic, or in other
resource-limited settings.
After the extraction-derivatization step, autosampler stabil-
ity of reconstituted samples was verified by re-injection of
QCs after a waiting period of 12 h at ambient temperature. No
statistical difference of analyte peak area was observed.
Pharmacokinetic investigation
Figure 5 shows representative concentration—time curves
of fluoxetine and norfluoxetine after oral administration of
fluoxetine. Because of to its high sensitivity, the outlined
method enabled the quantification of fluoxetine and
norfluoxetine up to 250 and 650 h, respectively, from only
10 μL blood samples.
The data processing estimated Cmax at 49.5 and
13.0 ng mL−1, Tmax at 6.0 and 48.0 h, t1/2 at 40.5 and
106 h, and AUC0-∞ at 1906 and 3170 h ng mL
−1 for
fluoxetine and norfluoxetine, respectively. The values
obtained were close to those usually found in literature based
on venous sampling [52, 53]. Although the investigation was
carried out on a single volunteer, the DBS sampling process
seems to be as suitable for performing pharmacokinetic
studies as classic venipuncture. However, further investiga-
tions are necessary to valuably compare results obtained from
capillary blood and DBS, and from plasma and capillary
specimens.
Conclusion
The objective of the work discussed in this article was to
perform quantitative analyses of antidepressants from 10 μL
whole blood using the DBS sampling procedure. Because of
its high sensitivity and selectivity, the use of NICI-MS-MS
enabled detection of compounds of interest up to 20 pg mL−1
without preconcentration. Optimization of the extraction step
by use of an appropriate solvent enabled combination of
derivatization and extraction in a single step, reducing the
sample-preparation time. Moreover, the use of fast GC
conditions makes this assay suitable for high-throughput
analysis. The method offered accurate quantification in terms
of trueness and precision of the four antidepressants tested
over their therapeutic concentration range.
DBS sampling coupled with GC-NICI-MS-MS was
successfully applied to a pharmacokinetic investigation of
fluoxetine and its active phase I metabolite on a healthy
volunteer. As the stability of the antidepressants in DBS was
shown to be unaffected by temperature, the pharmacokinetic
samples were shipped by mail without a refrigeration device
after collection by the volunteer himself at home. This
simplified procedure is particularly advantageous when
multiple samples are required.
Combining the numerous advantages of DBS sampling
with a sensitive and efficient GC-NICI-MS-MS technique,
this validated assay represents an interesting alternative for
microanalysis to traditional methods used in therapeutic
drug monitoring and pharmacokinetic studies.
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